Orchestra Biomed Holdings, INC Form 4 insider transactions

Orchestra BioMed's CFO, Andrew Taylor, had 3,452 shares withheld by the company to cover tax obligations related to restricted stock unit vesting.

Orchestra BioMed's Principal Accounting Officer, Joshua Aiello, reported a disposition of 241 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Orchestra BioMed Holdings, Inc. executive Darren Sherman reported a tax-related disposition of 5,588 common shares at $4.31 per share, maintaining significant beneficial ownership.

Orchestra BioMed's CFO, Andrew Taylor, reported a disposition of 8,670 shares for tax withholding related to restricted stock unit vesting.

Orchestra BioMed Holdings, Inc. CEO David P. Hochman reported a routine disposition of shares to cover tax obligations related to restricted stock unit vesting.

Orchestra BioMed Holdings, Inc. reports President and COO Darren Sherman's tax-related share withholding following restricted stock unit vesting.

Orchestra BioMed CFO Andrew Taylor reported the withholding of 3,071 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Orchestra BioMed Holdings, Inc. CEO and Chairperson David P. Hochman purchased 5,000 shares of common stock at a weighted average price of $4.07.

Orchestra BioMed Holdings CEO David P. Hochman reported a disposition of 3,283 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Orchestra BioMed Holdings, Inc. Director Jason Aryeh reported a planned acquisition of 1,000 shares of common stock at $2.45 per share, scheduled for September 19, 2025, which will increase his beneficial ownership to 108,482 shares.

Orchestra BioMed's Principal Accounting Officer, Joshua Aiello, engaged in a routine transaction involving the withholding of 203 shares of common stock to satisfy tax obligations related to restricted stock unit vesting.

Orchestra BioMed Holdings' CFO, Andrew Taylor, reported a disposition of shares to cover tax obligations related to restricted stock unit vesting.

Orchestra BioMed Holdings CEO David P. Hochman reported a tax withholding transaction related to restricted stock unit vesting, not a market sale.

Orchestra BioMed Holdings, Inc. Director and COO Darren Sherman reported a disposition of 40,340 shares for tax withholding related to RSU vesting.

Orchestra BioMed Holdings, Inc. Director Eric S. Fain acquired 5,760 shares of common stock at a weighted average price of $2.61.

Orchestra BioMed Holdings, Inc.'s President and COO, Darren Sherman, purchased 3,000 shares of common stock at $2.62 per share.

Orchestra BioMed Holdings, Inc. CEO and Chairperson David P. Hochman purchased 6,000 shares of common stock at an average price of $2.49.

Orchestra BioMed Holdings, Inc.'s Chief Financial Officer, Andrew Lawrence Taylor, purchased 2,000 shares of common stock at $2.55 per share.

Orchestra BioMed Holdings, Inc.'s Chief Financial Officer, Andrew Lawrence Taylor, was granted 80,000 restricted stock units as part of his compensation.

Orchestra BioMed Holdings, Inc. Director Jason Aryeh was granted 15,000 restricted stock units vesting in one year.

Orchestra BioMed Holdings, Inc. disclosed a future grant of 120,000 restricted stock units to President and Chief Operating Officer Darren Sherman, vesting over three years.

Orchestra BioMed Holdings, Inc. Director Pamela Ann Connealy received an award of 15,000 restricted stock units.

Orchestra BioMed Holdings, Inc. Director John Prosper Mack received an award of 15,000 restricted stock units, vesting one year from the August 7, 2025 grant date.

Orchestra BioMed Holdings, Inc. Director Eric S. Fain received an award of 7,500 restricted stock units, vesting one year from the grant date.

Orchestra BioMed Holdings, Inc. director Chris Cleary received an award of 15,000 restricted stock units.

Orchestra BioMed Holdings, Inc. CEO David P. Hochman received an award of 200,000 restricted stock units, vesting over three years.

Orchestra BioMed Holdings, Inc. Director David Pacitti received an award of 15,000 restricted stock units, vesting one year from the grant date.

Orchestra BioMed's Principal Accounting Officer, Joshua Aiello, was granted 15,000 restricted stock units vesting over three years.

RTW Investments, a 10% owner and director, reported the acquisition of over 3.6 million pre-funded warrants in Orchestra BioMed Holdings, Inc. with a future transaction date of August 4, 2025.

Perceptive Advisors LLC and related entities increased their beneficial ownership in Orchestra BioMed Holdings, Inc. through a recent public offering.